Cancer immunotherapy: Car T Cell Technology

A type of treatment in which a patient’s T cells (a type of immune cell) are altered in the laboratory so they will bind to cancer cells and destroy them. Blood from a vein in the patient’s arm flows through a tube to an apheresis machine (not shown), which eliminates the white blood cells, including the T cells, and directs the rest of the blood back to the patient. Then, the gene for a special receptor named a chimeric antigen receptor (CAR) is introduced into the T cells in the laboratory. Millions of the CAR T cells are developed in the laboratory and then given to the patient by infusion. The CAR T cells are able to bind to an antigen on the cancer cells and destroy them.

 

  • CAR-T cell therapy in Acute Lymphoblastic Leukaemia
  • CAR-T cells therapy in Chronic Lymphocytic Leukaemia
  • CAR-T cell in Multiple Myeloma

Related Conference of Cancer immunotherapy: Car T Cell Technology

March 24-25, 2025

25th World Congress on Cancer and Diagnostics

London, UK
March 24-25, 2025

10th World Conference on Breast and Cervical Cancer

Paris, France
April 28-29, 2025

35th Experts Meet On Cancer Research & Therapy

Paris, France
May 26-27, 2025

15th World Congress on Breast Cancer

Rome, Italy
June 16-17, 2025

26th World Congress on Cancer Summit

Amsterdam, Netherlands
July 14-15, 2025

5th World Congress on Breast Cancer

Berlin, Germany
July 28-29, 2025

45th Euro Congress on Cancer Science & Therapy

Paris, France
October 13-14, 2025

8th International Conference on Anti-Cancer Drugs & Therapies

Aix-en-Provence, France
October 20-21, 2025

21st International Conference on Cancer Research

Barcelona, Spain
November 24-25, 2025

43rd World Cancer Conference

Barcelona, Spain

Cancer immunotherapy: Car T Cell Technology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in